仟源醫藥(300254.SZ):2021年度預虧0.85億元-1.2億元
格隆匯1月24日丨仟源醫藥(300254.SZ)公佈2021年度業績預吿,公司預計實現2021年歸屬於上市公司股東的淨虧損為0.85億元-1.2億元;預計實現扣除非經常性損益後的淨虧損為1.27億元-1.62億元。
業績變動原因系:
1、報吿期內,由於公司產品鹽酸西那卡塞片、利伐沙班片在國家第五批藥品集中採購招標中未中標,且各省第五批藥品集中採購於2021年4季度開始陸續執行,導致公司2021年4季度營業收入有所下降,營業利潤出現虧損。
2、報吿期內,由於受新冠肺炎疫情等因素的影響,部分子公司存在商譽減值的跡象,公司根據評估機構商譽減值測試的初步結果計提了商譽減值準備。
3、報吿期內,由於公司粉針生產線產品如注射用美洛西林鈉舒巴坦鈉等銷量較少,導致相關產品庫存以及生產線產能過剩,公司計提了相關存貨跌價準備以及固定資產減值準備。
4、2019年11月,公司與江蘇疌泉醴澤健康產業創業投資基金(有限合夥)(以下簡稱“醴澤基金”)及自然人張宇簽署《關於投資江蘇嘉逸醫藥有限公司之合作協議》,共同設立南通恆嘉藥業有限公司受讓江蘇嘉逸醫藥有限公司的部分股權。協議約定公司對醴澤基金、張宇的出資款負有回購義務。因此,公司將醴澤基金、張宇對南通恆嘉藥業有限公司的出資作為金融負債,並按照約定的年化收益率計提相關金融負債產生的財務費用,導致報吿期內計提利息支出約3200萬元。
5、報吿期內,預計非經常性損益對淨利潤的影響約4200萬元,主要為各類政府補貼約3000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.